80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]郭慈仁,陳桂林,江信燕,等.P53、ER、PR在Ⅰ期子宮內(nèi)膜癌中的表達(dá)及其與臨床病理特征的相關(guān)性分析[J].福建醫(yī)藥雜志,2021,43(01):17-20.
　GUO Ciren,CHEN Guilin,JIANG Xinyan,et al.Expression of P53, estrogen receptor and progesterone receptor in stageⅠendometrial carcinoma and their relationship with clinicopathological characteristics[J].FUJIAN MEDICAL JOURNAL,2021,43(01):17-20.
點(diǎn)擊復(fù)制

P53、ER、PR在Ⅰ期子宮內(nèi)膜癌中的表達(dá)及其與臨床病理特征的相關(guān)性分析()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
43
期數(shù):
2021年01期
頁(yè)碼:
17-20
欄目:
臨床研究
出版日期:
2021-02-10

文章信息/Info

Title:
Expression of P53, estrogen receptor and progesterone receptor in stageⅠendometrial carcinoma and their relationship with clinicopathological characteristics
文章編號(hào):
1002-2600(2021)01-0017-04
作者:
郭慈仁; 陳桂林; 江信燕; 石懷景; 林潔1
福建省腫瘤醫(yī)院 福建醫(yī)科大學(xué)附屬腫瘤醫(yī)院婦科(福州 350014)
Author(s):
GUO Ciren;  CHEN Guilin;  JIANG Xinyan;  SHI Huaijing;  LIN Jie.
Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Department of Tumor Gynecology, Fuzhou,Fujian 350014, China
關(guān)鍵詞:
P53;  雌激素受體;  孕激素受體;  子宮內(nèi)膜癌
Keywords:
P53;  estrogen rcceptor;  progesterone receptor;  endometrial carcinoma
分類號(hào):
R737.33
文獻(xiàn)標(biāo)志碼:
B
摘要:
目的 觀察Ⅰ期子宮內(nèi)膜癌中P53、雌激素受體(ER)、孕激素受體(PR)的表達(dá)情況,并探討其與臨床病理特征的關(guān)系。方法 應(yīng)用免疫組化S-P法檢測(cè)2015年5月至2020年7月我院收治的188例臨床診斷為Ⅰ期的子宮內(nèi)膜癌患者術(shù)后癌組織標(biāo)本中P53、ER、PR的表達(dá)情況,應(yīng)用統(tǒng)計(jì)學(xué)方法分析其表達(dá)與臨床病理特征間的關(guān)系。結(jié)果 1)P53、ER、PR在Ⅰ期子宮內(nèi)膜癌中的陽(yáng)性表達(dá)率分別為60.6%、90.4%和85.6%; 2)P53的表達(dá)與組織學(xué)類型、淋巴結(jié)轉(zhuǎn)移有關(guān)(均P<0.05),而與年齡、組織學(xué)分級(jí)、脈管癌栓及深肌層浸潤(rùn)無(wú)關(guān)(均P>0.05); ER、PR的表達(dá)與組織學(xué)類型、組織學(xué)分級(jí)有關(guān)(均P<0.05),而與年齡、淋巴結(jié)轉(zhuǎn)移、脈管癌栓及深肌層浸潤(rùn)無(wú)關(guān)(均P>0.05)。結(jié)論 聯(lián)合檢測(cè)P53、ER、PR有助于了解早期子宮內(nèi)膜癌的生物學(xué)行為,對(duì)術(shù)后內(nèi)分泌治療及預(yù)后評(píng)估有一定的參考價(jià)值。
Abstract:
Objective To observe the expression of P53, estrogen receptor(ER)and progesterone receptor(PR)in stage Ⅰ endometrial carcinoma and to explore their relationship with clinicopathological characteristics.Methods S-P immunohistochemical technique was used to detect the expression of P53, ER and PR in the postoperative cancer tissues of 188 patients with stage Ⅰ endometrial carcinoma who were clinically diagnosed in our hospital form May 2015 to July 2020, the relationship between its expression and clinicopathological features was statistically analyzed at the same time.Results The positive expression rates of P53, ER and PR in stage Ⅰ endometrial carcinoma were 60.6%,90.4% and 85.6%, respectively.The expression of P53 was significant association with histological type and lymph nodes metastasis(P<0.05), but not with patient age, histological grade, lymphatic vascular space infiltration and deep muscle invasion(P>0.05).The expression of ER and PR was significant association with histological type and histological grade(P<0.05), but not with patient age, lymph nodes metastasis, lymphatic vascular space infiltration and deep muscle invasion(P>0.05).Conclusion The results of our experiment suggest that combined detection of P53, ER and PR is helpful to understand the biological behavior of early endometrial carcinoma and has certain reference value for postoperative prognosis evaluation.

參考文獻(xiàn)/References:

[1] Jemal A, Bray F, Center M M, et al.Global cancer statistics 2008 [J]. CA Cancer J Clin,2011,61(2):69-90.
[2] 夏朝暉,李文敏,何雯.子宮內(nèi)膜癌PR、ER、PTEN、P53及Ki-67的表達(dá)情況及其與預(yù)后的相關(guān)性分析[J].解放軍醫(yī)藥雜志,2017,29(7):22-25.
[3] Yeramian A, Moreno-Bueno G, Dolcet X, et al.Endometrial carcinoma:molecular alterations involved in tumor develo-pment and progression[J].Oncogene,2013,32(4):403.
[4] Murali R, Soslow R A, Wergelt B.Classification of endometrial carcinoma: more than two type[J].The Lancet Oncology, 2014,15(7):268.
[5] 趙琦.子宮內(nèi)膜癌組織中ER、PR、P53、Ki-67的表達(dá)及其與臨床病理特征的相關(guān)性分析[J].中國(guó)實(shí)驗(yàn)診斷學(xué),2017,21(2):256-258.
[6] 夏良兵.子宮內(nèi)膜癌組織中的P53及Ki-67蛋白的表達(dá)及與臨床病理特征的關(guān)系分析[J].中國(guó)實(shí)驗(yàn)診斷學(xué),2019,23(5):857-859.
[7] 王娟,李軍,郭燦燦.雌激素受體、孕激素受體、P53及Ki-67 在子宮內(nèi)膜癌組織中的表達(dá)及其與臨床病理特征的關(guān)系[J].海南醫(yī)學(xué),2017,28(2):211-213.
[8] Bokhman J V.Two pathogenetic types of endometrial car-cinoma[J].Gynecol Oncol,1983,15(1):10-17.
[9] 王婧元,戴一博,王志啟,等.子宮內(nèi)膜透明細(xì)胞癌的分子特征研究進(jìn)展[J]. 現(xiàn)代婦產(chǎn)科進(jìn)展,2019,28(8):628-630.
[10] Lobo FD, Thomas E.Type Ⅱ endometrial carcers:A case series[J].J Midlife Health, 2016,7(2):69-72.
[11] Masjeed NMA, Khandeparkar SGS, Joshi AR, et al.Immunohistochemical study of ER, PR, Ki67 and P53 in endometrial hyperplasias and endometrial carcinomas[J].J Clin Diagn Res,2017,11(8): 31-34.
[12] Allo G, Bernardini M Q, Wu R C, et al.ARIDIA loss correlaes with mismatch repair deficiency and intact P53 expression in high-grade endometrial carcinomas[J].Modern Pathology, 2014,27(1):255.
[13] Nguyen T T, Hachisuga T, Urabe R, et al.Significance of P53 expression in background endometrium in endometrial carcinomas[J].Virchows Archiv, 2015,466(6):695.
[14] Karim S, Ali A.Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India [J].World J Gastroenterol, 2009,15(11): 1381-1387.
[15] 牛希賢.ER、PR、P53和HER2在正常子宮內(nèi)膜和子宮內(nèi)膜癌中的表達(dá)相關(guān)性分析[J].醫(yī)藥論壇雜志,2015,36(10):58-60.

更新日期/Last Update: 2021-02-10